Wave Life Sciences announced on Monday 29th March 2021 that it will discontinue development of two of their three Huntingtin lowering ASO drugs as analysis of the phase 1b/2a trials PRECISION HD1 and PRECISION HD2 showed no evidence of a dose response across the dose levels tested. This is another sobering reminder that therapeutic development, especially in a disease as complex as HD, is difficult and prone to set-backs. It however also demonstrates that high quality clinical trials in HD are ongoing and yielding results, even if the outcomes are disappointing so far. Irrespective of the outcome, every properly conducted and analysed clinical trial represents a step towards finding effective treatments, and every study participant helps to advance the field forward towards this shared goal.
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials: News Release